 |
March 12, 2018, 04:44:58 PM |
|
Healthcare systems are often required to make the difficult decision of whether to reimburse costly
pharmacological therapies and provide access for patients while taking into account their limited
resources. Innovative pricing approaches have the ability to overcome the challenges faced by
healthcare systems when assessing the funding of new drugs, to enable the implementation of
‘flexible’ pricing schemes to assess the price of treatment in relation to the benefits it delivers.
Unfortunately, healthcare systems around the world lack the relevant infrastructure to track
and implement innovative pricing models such as value-based pricing agreements, and so are
reluctant to adopt such innovative policies. This results in novel pharmacological therapies
being denied to patients who are most at need, an opportunity missed to decrease the long
term economic and disease burden on health systems, and a barrier to reimbursement for
manufacturers.
|
